Jann MW

References (7)

Title : Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis - Jann_2004_Pharmacotherapy_24_1759
Author(s) : Jann MW
Ref : Pharmacotherapy , 24 :1759 , 2004
PubMedID: 15585443

Title : Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors - Jann_2002_Clin.Pharmacokinet_41_719
Author(s) : Jann MW , Shirley KL , Small GW
Ref : Clinical Pharmacokinetics , 41 :719 , 2002
PubMedID: 12162759

Title : Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly - VanDenBerg_2000_Drugs.Aging_16_123
Author(s) : VanDenBerg CM , Kazmi Y , Jann MW
Ref : Drugs & Aging , 16 :123 , 2000
PubMedID: 10755328

Title : Supportive care for the patient with Alzheimer's disease - Jann_2000_J.Am.Pharm.Assoc.(Wash)_40_S50
Author(s) : Jann MW , Brandt N
Ref : J Am Pharm Assoc (Wash) , 40 :S50 , 2000
PubMedID: 11029868

Title : Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease - Jann_2000_Pharmacotherapy_20_1
Author(s) : Jann MW
Ref : Pharmacotherapy , 20 :1 , 2000
PubMedID: 10641971

Title : Pharmacology and clinical efficacy of cholinesterase inhibitors - Jann_1998_Am.J.Health.Syst.Pharm_55 Suppl 2_S22
Author(s) : Jann MW
Ref : Am J Health Syst Pharm , 55 Suppl 2 :S22 , 1998
PubMedID: 9809108

Title : Preclinical pharmacology of metrifonate - Jann_1998_Pharmacotherapy_18_55
Author(s) : Jann MW
Ref : Pharmacotherapy , 18 :55 , 1998
PubMedID: 9543466